

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel in the order listed for Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME		POSITION TITLE	
Kattan, Michael W. Ph.D.		Chairman, Department of Quantitative Health Sciences Cleveland Clinic	
eRA COMMONS USER NAME			
MICHAELKATTAN		Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Professor, Division of General Medical Sciences, Cancer Center, School of Medicine, Case Western Reserve University Professor, Department of Epidemiology and Biostatistics, School of Medicine, Case Western Reserve University	
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
University of Arkansas, Fayetteville, Arkansas	B.S.	1987	Food Science
University of Arkansas, Fayetteville, Arkansas	M.B.A.	1989	Computer Information Systems / Quantitative Analysis
University of Houston, Houston, Texas	Ph.D.	1993	Business Administration, Major in Management Information Systems, minor in Statistics
Baylor College of Medicine, Houston, Texas	Postdoctoral Training	1994	Medical Informatics

A. Positions and Honors.**Positions and Employment**

1994 – 1998 Assistant Professor of Urology and Medical Informatics, Scott Department of Urology and the Information Technology Program, Baylor College of Medicine, Houston, Texas

1998 – 2002 Assistant Attending Outcomes Research Scientist, Departments of Urology and Epidemiology and Biostatistics, Memorial Hospital for Cancer and Allied Diseases, New York, NY

1998 – 2002 Assistant Member, Memorial Sloan-Kettering Cancer Center, New York, NY

2003 – 2004 Associate Attending Outcomes Research Scientist, Departments of Urology and Epidemiology and Biostatistics, Memorial Hospital for Cancer and Allied Diseases, New York, NY

2003 – 2004 Associate Member, Memorial Sloan-Kettering Cancer Center, New York, NY

2003 – 2004 Associate Professor of Clinical Public Health, Cornell University, New York, NY

2003 – 2004 Associate Professor of Biostatistics in Urology, Cornell University, New York, NY

2004 Chairman, Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

2006 Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio

2006 Professor, Division of General Medical Sciences, Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio

2007 Professor, Department of Epidemiology and Biostatistics, School of Medicine, Case Western Reserve University, Cleveland, Ohio

Other Experience and Professional Memberships

1997-2000 Medical Decision Making, Editorial Board
1999-2002 Urologic Oncology, Associate Editor
1996- 2007 Journal of Urology, Board of Consultants
2002-Present Clinical Genitourinary Cancer, Section Editor
2003-Present Urologic Oncology: Seminars and Original Investigation, Associate Editor
2005-2008 Medical Decision Making, Editorial Board
2005-Present Nature Clinical Practice Urology, Advisory Board
2006-Present Cancer Investigation, Editorial Board

Honors

1986–1987 Institute of Food Technologists National Scholarship
1992 International Conference on Information Systems Doctoral Consortium
1992 Melcher College of Business Administration Award for Outstanding Teaching by a Doctoral Candidate
1993 Melcher College of Business Administration Dean's Distinguished Dissertation Award

B. Selected peer-reviewed publications (in chronological order):

(Publications selected from over 275 peer-reviewed publications)

- Kattan MW, Adams DA, Parks MS. A comparison of machine learning with human judgment. *J Manag Inf Sys* 1993;9(4):37-57S.
- Kattan MW, Hess KR, Beck JR. Experiments to determine whether recursive partitioning (CART) or an artificial neural network overcome theoretical limitations of Cox proportional hazards regression. *Computers Biomed Res* 1998;31(5):363-373.
- Kattan MW, Eastham JA, Stapleton AMF, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. *J Natl Ca Inst* 1998;90(10):766-771.
- Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. *J Clin Oncol* 2000;18(19):3352-3359.
- Kattan MW, Fearn PA, Leibel S, Potters L. The definition of biochemical failure in patients treated with definitive radiotherapy. *Int J Radiat Oncol Biol Phys* 2000;48(5):1469-1474.
- Kattan MW, Potters L, Blasko JC, Beyer DC, Fearn PA, Cavanagh W, Leibel S, Scardino PT. Pretreatment nomogram for predicting freedom from recurrence following permanent prostate brachytherapy in prostate cancer. *Urology* 2001;58(3):393-399.
- Kattan MW, Leung DHY, Brennan MF. A postoperative nomogram for 12-year sarcoma-specific death. *J Clin Oncol* 2002;20(3):791-796.
- Kattan MW, Scardino PT. Prediction of progression: nomograms of clinical utility. *Clinical Prostate Cancer* 2002;1(2):90-96.
- Kattan MW, Eastham JA. Algorithms for PSA recurrence after treatment of localized prostate cancer. *Clinical Prostate Cancer* 2003;1:221-226.
- Kattan MW, Shariat SF, Andrews B, Zhu K, Canto E, Matsumoto K, Scardino PT, Ohori M, Wheeler TM, Slawin KM. The addition of interleukin-6 soluble receptor and transforming growth factor B1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. *J Clin Oncol* 2003; 21(19): 3573-3579.
- Kattan MW. Judging new markers by their ability to improve predictive accuracy. *J Natl Cancer Inst.* 2003;95:634-635.
- Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, Reuter V, Graefen M, Hammerer PG, Erbersdobler A, Huland H, Kupelian P, Klein E, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG, Scardino PT and Kattan MW. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. *J Urol* 2003; 170: 1798-1803.
- Kattan MW. Comparison of Cox regression with other methods for determining prediction models and nomograms. *J Urol* 2003; 170: S6-S10.

- Kattan MW, Zelefsky MJ, Kupelian PA, Cho D, Scardino PT, Fuks Z, Leibel SA. A pretreatment nomogram that predicts 5 year probability of metastasis following 3-D conformal radiation therapy for localized prostate cancer. *J Clin Oncol* 2003; 21(24):4568–4571.
- Kattan MW. Comparing treatment outcomes using utility assessment for health-related quality of life. *Oncology* 2003; 17(12): 1687-1693.
- Kattan MW, Vickers AJ. Incorporating predictions of individual patient risk in clinical trials. *Urol Oncol*. 2004 Jul-Aug;22(4):348-52.
- Kattan MW. Evaluating a new marker's predictive contribution. *Clin Can Res* 2004; 10: 882-824.
- Elkin EB, Cowen ME, Cahill D, Steffel M, Kattan MW. Preference assessment method affects decision analytic recommendations: a prostate cancer treatment example. *Med Dec Making*. 2004 Sep-Oct;24(5):504-10.
- Kattan MW. When and how to use informatics tools in caring for urologic patients. *Nature Clin Practice Urol*. Apr 2005; 2(4):183-190.
- Katz EM, Kattan MW. How to judge a tumor marker. *Nat Clin Pract Oncol*. 2005 Oct;2(19):482-483.
- Befort CA, Zelefsky MJ, Scardino PT, Borrayo E, Giesler RB, Kattan MW. A measure of health-related quality of life among localized prostate cancer patients: result from on-going scale development. *Clin Prostate Cancer*. 2005 Sept;4(2):100-108.
- Cowen ME, Halsyamani LK, Kattan MW. Predicting life expectancy for men with clinically localized prostate cancer. *J Urol*. 2006 Jan;175(1):99-103.
- Stephenson AJ, Scardino PT, Eastham JA, Bianco, JR FJ, Dotan ZA, Fearn PA, Kattan MW. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. *JNCI*. 2006 May 17;98(10):715-717.
- Kattan MW, Ficarra V, Artibani W, Cosciani Cunico S, Fandella A, Martignoni G, Novara G, Prayer Galetti T, Zattoni F and GUONE Penile Cancer Project Cancer Project Members. Nomogram predictive of cancer-specific survival in patients undergoing partial or total amputation for squamous cell carcinoma of the penis. *J. Urol*. 2006 Jun;175(6):2103-2108.
- Elkin EB, Vickers AJ, Kattan MW. Primer: using decision analysis to improve clinical decision making in urology. *Nat Clin Pract Urol*. 2006 Aug;3(8):439-448.
- Fu A, Kattan MW. Racial and ethnic differences in preference-based health status measure. *Curr Med Res Opin*. 2006 Dec;22(12):2439-2448.
- Stone NN, Potters L, David BJ, Ciezki JP, Zelefsky MJ, Roach M, Fearn PA, Kattan MW. Customized dose prescription for permanent prostate brachytherapy: Insights from a multicenter analysis of dosimetry outcomes. *Int J Radiat Oncol Biol Phys*. 2007 Dec1;69(5):1472-1477
- Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki BA, Thompson IM, Aronson WJ, Terris MK, Kane CJ, Presti, Jr. JC, Amling CL, Freedland SJ. The effect of race/ethnicity on the accuracy of the 2001 Partin tables for predicting pathologic stage of localized prostate cancer. *J Urol*. 2008 Jan;71(1):151-155
- Richstone L, Bianco FJ, Shah H, Kattan MW, Eastham JA, Scardino PT, Scherr D. Radical prostatectomy in men seventy years or older: impact of age on upgrading upstaging and preoperative nomogram accuracy. *BJU Intl*. 2008 Mar;101(5):541-546
- Kattan MW Gönen M, Jarnagin WR, DeMattero R, D'Angelica M, Weiser M, Blumgart LH, Fong Y. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. *Ann Surg*. 2008 Feb;247(2):282-287.

C. Research Support

Ongoing Research Support

Pamela B. Davis, M.D., Ph.D. (PI)	2007-2012	1.80 calendar
National Institutes of Health /		
Clinical and Translational Science Aware \$64,000,000 (\$79,555 annual direct costs)		
"Translational Methodologies" UL1 RR 024989-01. Case Western Reserve University, in partnership with the Cleveland Clinic, University Hospitals and MetroHealth Medical Center formed the Clinical & Translational Science Collaborative (CTSC) in September 2007. The National Institutes of Health (NIH) awarded the partners \$64 million to become part of a national consortium designed to transform how clinical and translational research is conducted, ultimately enabling researchers to provide new treatments more efficiently and quickly to patients. The consortium, funded through NIH's Clinical and Translational Science Awards, was formed in 2006 with an initial 12 academic health centers located nationwide.		

Role: Co-Director

Ongoing Research Support (continued)

Michael W. Kattan (PI) 06/20/2006-12/31/2009 1.80 calendar
AstraZeneca \$1,153,200

“Using an EHR-based Clinical Data Repository to Determine Prescribing Patterns and Outcomes”

The research project aims to contribute to AZ's knowledge of the utilization of Electronic Health Record-derived data for understanding the prescribing patterns and outcomes in a large health care group, with the ultimate goal of expanding knowledge for improved adverse drug event management.

Role: Principal Investigator

Robert J. Weil (PI) 01/01/2006-12/31/2011 4.80 calendar
Department of Defense/ Center of Excellence \$1,748,985

“Studies for Eradication of Brain Metastasis from Breast Cancer”

The major goal of this project is to use translational clinical research design to understand, treat and prevent brain metastasis from breast cancer.

Role: Co- Investigator

Pending Research Support

Robert J. Fox, M.D. (PI)
National Multiple Sclerosis Society \$1,153,200

“Risk Tolerance and Utility of Multiple Sclerosis Therapies”

A survey will be administered annually to 5,000 subjects selected from the NARCOMS database. This will evaluate demographic, disease, psychosocial factors in decision making about risk and DMTs. These include health literacy, information monitoring, tolerance of ambiguity, self efficacy and information style. Furthermore, a utility analysis will be performed. This will consist of a standard gamble scheme using 5 scenarios. The survey is repeated 3 time annually to assess changes over time.

Role: Co-Investigator

Completed Research Projects in the last 3 years

Martin Ross Weiser (PI) 5/01/2006-7/31/2007

American Joint Committee on Cancer

“Improving Colorectal Cancer Staging with Nomograms”

The main goal of this project is to report anatomic characteristics used in proposed staging algorithms from this research using the data elements defined in the Collaborative Staging System.

Role: Co-Investigator

Michael W. Kattan (PI)
NCI Contract/ Division of Cancer Control and Population Sciences 09/01/2006-11/30/2006

“Validation of Clinicians Survival System”

The aim of this project is three fold; 1. Assess the discriminatory power of the current model to predict those at a higher risk of dying from cancer. 2. Quantify the added benefit of including comorbidity information in the survival system. 3. Investigate the need for additional modeling and prepare a report of recommendations.

Role: Principal Investigator